Knowledge Hub

Aotearoa's neuroendocrine cancer community. Free patient information, peer support and advocacy for New Zealanders affected by NETs.

info@neuroendocrinecancer.org.nz

PO Box 87064, Meadowbank, Auckland 1742

Patient support

Patient support hub
Book a call with our nurse
Zoom-In monthly sessions
Peer catch-ups
What's on
Hardship fund

Knowledge Hub

All resources
Patient Guide
Patient stories
Understanding NETs
SCAN 2025 report
Glossary

Get involved

Donate
Fundraise for NECNZ
Ways to help
Newsletter signup
For clinicians

Organisation

About NECNZ
Meet the team
Founders
News
Contact
Privacy
Terms of use
Accessibility

Registered charity CC49802 · NZBN 9429046320391 · Proud member of the International Neuroendocrine Cancer Alliance
© 2026 NeuroEndocrine Cancer New Zealand

Knowledge Hub

Information you can trust.

Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.

Search the Knowledge Hub

FormatAll Articles Booklets Videos Tools External

TopicAll Understanding NET cancer Living with NETs Patient stories NET resources Resources for HCPs Programmes & events

Clear all filters

12 resources

Page 1 of 1

Understanding NET cancer1 Jul 2026
SCAN 2025 – NET patient survey (New Zealand)
The New Zealand reading of the global SCAN 2025 survey of neuroendocrine cancer patients and clinicians – how our care compares with the world.
Read
Understanding NET cancer20 Mar 2026
Types of scans for NET Cancers

There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.

Read

Understanding NET cancer20 Mar 2026

Grades of Neuroendocrine (NET) Cancers

What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.

Read

Understanding NET cancer20 Mar 2026

Types of Neuroendocrine Tumours

Neuroendocrine Tumours (NETs) is an umbrella name for a number of different types of tumours, which can arise in different areas of the body. It can be…

Read

Understanding NET cancer16 Mar 2026

Treatments for NETs

Treatments for neuroendocrine cancers vary from person to person and may be one or more of the options listed below.

Read

Understanding NET cancer12 Mar 2026

A second PRRT in the FDA pipeline: 177Lu-edotreotide decision due August 2026

The FDA is expected to decide on ITM-11 (177Lu-edotreotide) for GEP-NETs by 28 August 2026, based on the Phase 3 COMPETE trial results.

Read

Understanding NET cancer20 Jan 2026

Early signals from alpha-emitter PRRT in SSTR2-positive NETs

A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.

Read

Understanding NET cancer20 Jan 2026

Understanding Neuroendocrine

Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.

Read

Understanding NET cancer26 Mar 2025

Cabozantinib approved by the FDA for previously treated advanced NETs

The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.

Read

Understanding NET cancer15 Sept 2024

NETTER-2 supports PRRT as a first-line option in advanced GEP-NETs

The Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.

Read

Understanding NET cancer1 Jun 2024

When NET cancers run in families: inherited syndromes

Most neuroendocrine cancers aren't inherited, but a small number are linked to hereditary syndromes like MEN1, MEN2 and VHL. Here's what to know.

Read

Understanding NET cancer15 Jan 2024

Understanding Neuroendocrine (NET) Cancers

Neuroendocrince Cancer NZ is an organisation dedicated to revolutionising the way that neuroendocrine tumours are diagnosed and managed in New Zealand.

Read